AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Mary Brown's operated mainly in Newfoundland (about 20 locations with 2 locations in Halifax and 1 in Ontario) until the late 1970s, when it began expanding in Ontario, Alberta and Nova Scotia. In 2010, there were 38 locations in Newfoundland and Labrador, 30 locations in Ontario, 12 in Alberta and 3 in Nova Scotia, for an approximate total of 83. As of 2017, Mary Brown's has expanded into the United States, specifically in Florida. Drive-through and delivery services are available at some locations. The restaurant chain, started by Newfoundlanders Pat Tarrant and Cyril Fleming in 1969, was named after Mary Brown, the wife of a fried chicken recipe creator. The headquarters are in Markham, Ontario.
The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 is one of three major drug control treaties currently in force. It provides additional legal mechanisms for enforcing the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. The Convention entered into force on November 11, 1990. As of June 2020, there are 191 Parties to the convention. These include 186 out of 193 United Nations member states (not Equatorial Guinea, Kiribati, Papua New Guinea, Solomon Islands, Somalia, South Sudan, or Tuvalu) and the Holy See, the European Union, the Cook Islands, Niue, and the State of Palestine.
In the wild, adult Komodo dragons usually weigh around 70 kg (150 lb), although captive specimens often weigh more. According to Guinness World Records, an average adult male will weigh 79 to 91 kg (174 to 201 lb) and measure 2.59 m (8.5 ft), while an average female will weigh 68 to 73 kg (150 to 161 lb) and measure 2.29 m (7.5 ft). The largest verified specimen in captivity was 3.1–3.13 m (10 ft 2 in – 10 ft 3 in) long and weighed 166 kg (366 lb), including its undigested food. The largest wild specimen had a length 3.04 m (10 ft), a snout-vent length (SVL) 1.54 m (5 ft 1 in) and a mass of 81.5 kg (180 lb) excluding stomach contents. The heaviest reached a mass of 87.4 kg (193 lb). The study noted that weights greater than 100 kg (220 lb) were possible but only after the animal had consumed a large meal. The Komodo dragon has a tail as long as its body, as well as about 60 frequently replaced, serrated teeth that can measure up to 2.5 cm (1 in) in length. Its saliva is frequently blood-tinged because its teeth are almost completely covered by gingival tissue that is naturally lacerated during feeding. It also has a long, yellow, deeply forked tongue.
Sources: en.wikipedia.org
== Chemistry literature == Scientific literature Scientific journal Academic journal List of important publications in chemistry List of scientific journals in chemistry List of science magazines Scientific American
(1914–2006), American physicist and chemist who won the 2002 Nobel Prize in Physics for detecting neutrinos emitted from the Sun Humphry Davy (1778–1829), British chemist, discovered several alkaline earth metals Serena DeBeer (born 1973), American chemist known for developing X-ray based spectroscopic probes of electronic structure Peter Debye (1884–1966), Dutch chemist who improved the theory of electrical conductivity in electrolyte solutions, winner of the 1936 Nobel Prize in Chemistry Johann Deisenhofer (born 1943), German biochemist who determined the three-dimensional structure of a protein complex found in photosynthetic bacteria, 1988 Nobel Prize in Chemistry Margarita del Val (born 1959), Spanish chemist, immunologist, and virologist, coordinator of the Salud Global ("Global Health") platform Nathalie Demassieux (1884–1961), French mineral chemist and academic who worked on the complex halogenated salts of lead Gautam Radhakrishna Desiraju (born 1952), Indian chemist known for work on crystal engineering and weak hydrogen bonds James Dewar (1842–1923), British chemist and physicist known for his invention of the vacuum flask and its usefor studying the liquefaction of gases François Diederich (1952–2020), Luxembourg chemist known for molecular recognition studies with biological receptors Otto Diels (1876–1954), German chemist, winner of the 1950 Nobel Prize in Chemistry for the Diels–Alder reaction, a method for cyclohexene synthesis Robert Dirks (1978–2015), American computational chemist known for work on DNA nanotechnology
The epithelium is the innermost layer. It is where most digestive, absorptive and secretory processes occur. The lamina propria, the underlying layer of loose connective tissue within the mucosa. The muscularis mucosae, a thin layer of smooth muscle. The epithelium, the most exposed part of the mucosa, is a glandular epithelium with many goblet cells. Goblet cells secrete mucus, which lubricates the passage of food along and protects the intestinal wall from digestive enzymes. In the small intestine, villi are folds of the mucosa that increase the surface area of the intestine. The villi contain a lacteal, a vessel connected to the lymph system that aids in the removal of lipids and tissue fluids. Microvilli are present on the epithelium of a villus and further increase the surface area over which absorption can take place. Numerous intestinal glands as pocket-like invaginations are present in the underlying tissue. In the large intestines, villi are absent and a flat surface with thousands of glands is observed. Underlying the epithelium is the lamina propria, which contains myofibroblasts, blood vessels, nerves, and several different immune cells, and the muscularis mucosa which is a layer of smooth muscle that aids in the action of continued peristalsis and catastalsis along the gut.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.